| Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.
This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data.
The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of the sponsor or the commercial supporter.
Faculty Disclosure
Mitch Dowsett, PhD, has indicated significant relationships with the following companies: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, and Pharmacia & Upjohn.
Matthew J. Ellis, MD, PhD, has indicated significant relationships with the following companies: Genentech, Inc, and Novartis Pharmaceuticals Corporation.
Daniel F. Hayes, MD, has indicated significant relationships with the following companies: Agouron Pharmaceuticals, Inc; Amgen Inc; AstraZeneca Pharmaceuticals LP; Aventis Pharmaceuticals; Bristol-Myers Squibb Company; Coley Pharmaceutical Group; Genentech, Inc; Genetics Institute; Genta Inc; Immunicon Corporation; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; and Wyeth-Ayerst Pharmaceuticals.
Clifford A. Hudis, MD, has indicated significant relationships with the following companies: Amgen Inc; Aventis Pharmaceuticals; Bristol-Myers Squibb Company; Eli Lilly and Company; Ortho Biotech Products, LP; and Pharmacia & Upjohn.
Richard L. Theriault, DO, MBA, has indicated significant relationships with the following company: Novartis Pharmaceuticals Corporation.
|